GPER1
ENSG00000164850
Target class
GPCR
Chromosome
7
- Chemical probe available
- Yes
- Target name
- GPER1
- Gene name
- G protein-coupled estrogen receptor 1
- Gene symbol
- GPER1
- Protein name
- G-protein coupled estrogen receptor 1 (Chemoattractant receptor-like 2) (Flow-induced endothelial G-protein coupled receptor 1) (FEG-1) (G protein-coupled estrogen receptor 1) (G-protein coupled receptor 30) (GPCR-Br) (IL8-related receptor DRY12) (Lymphocyte-derived G-protein coupled receptor) (LYGPR) (Membrane estrogen receptor) (mER)
- FEG-1
- GPCR-Br
- LERGU
- LERGU2
- DRY12
- LyGPR
- CEPR
- CMKRL2
- GPR30
- GPER
- Gene biotype
- Protein coding
- Gene family
- G protein-coupled estrogen receptor
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 30.42
- Tissue specificity (Gini)
- 0.321
- Tissue specificity (tau)
- 0.722
- KEGG gene identifiers
- hsa:2852
- Protein interaction confidence
- 0.840214
- Protein interaction partners
- 14
- R-HSA-375276
- R-HSA-418594
- R-HSA-9634597
- End position
- 1094511
- Start position
- 1082208
- Chromosome
- 7
- Strand
- Forward
- Nucleus. Cytoplasm . Cytoplasm, perinuclear region. Cytoplasm, cytoskeleton. Cell membrane
- Multi-pass membrane protein. Basolateral cell membrane
- Multi-pass membrane protein. Cytoplasmic vesicle membrane
- Multi-pass membrane protein. Early endosome. Recycling endosome. Golgi apparatus membrane
- Multi-pass membrane protein . Golgi apparatus, trans-Golgi network. Endoplasmic reticulum membrane
- Multi-pass membrane protein. Cell projection, dendrite . Cell projection, dendritic spine membrane
- Multi-pass membrane protein . Cell projection, axon . Postsynaptic density . Mitochondrion membrane
- Multi-pass membrane protein . Note=Colocalized with BSN to the active zone of presynaptic density. Colocalized with DLG4/PSD95 and neurabin-2 PPP1R9B in neuronal synaptosomes (By similarity). Endocytosed in a agonist- and arrestin-independent manner. Colocalized with RAMP3 and clathrin-coated pits at the plasma membrane. Colocalized with transferrin receptor at the plasma membrane and perinuclear region. Accumulated and colocalized with RAB11 proteins in recycling endosomes and trans-Golgi network (TGN), but does neither recycle back to the cell surface nor traffics to late endosome or lysosome. Colocalized with calnexin in the endoplasmic reticulum. Traffics to intracellular sites via cytokeratin intermediate filaments like KRT7 and KRT8 after constitutive endocytosis in epithelial cells. Colocalized with EGFR in the nucleus of agonist-induced cancer-associated fibroblasts (CAF). .
- Cytosol
- Nucleoli
- Nucleoplasm
- Vesicles
Publication evidence
- PubMed 18566127
- Tissue specificity (tau)
- 0.722433
- Expression inequality (Gini)
- 0.321419
Expression in transcripts per million
- Stomach
- 30.42
- Cells - EBV-transformed lymphocytes
- 20.07
- Nerve - Tibial
- 18.22
- Thyroid
- 17.01
- Adipose - Subcutaneous
- 15.62
Expression in transcripts per million
- Stomach30.42
- Cells - EBV-transformed lymphocytes20.07
- Nerve - Tibial18.22
- Thyroid17.01
- Adipose - Subcutaneous15.62
- Colon - Sigmoid15.41
- Artery - Tibial14.19
- Adrenal Gland13.31
- Liver13.2
- Esophagus - Gastroesophageal Junction12.47
- Brain - Putamen (basal ganglia)12.04
- Adipose - Visceral (Omentum)11.74
- Spleen11.59
- Brain - Cortex11.47
- Brain - Caudate (basal ganglia)11.18
- Esophagus - Muscularis10.59
- Cervix - Endocervix10.31
- Artery - Coronary10.24
- Breast - Mammary Tissue10.2
- Uterus10.07
- Prostate9.93
- Lung9.67
- Pituitary9.66
- Fallopian Tube9.52
- Brain - Substantia nigra9.36
And 29 more, listed on the interactive page.
- GO:0001934
- GO:0002695
- GO:0007186
- GO:0007189
- GO:0008284
- GO:0010628
- GO:0010629
- GO:0010948
- GO:0030335
- GO:0030518
- GO:0032962
- GO:0043401
- GO:0045742
- GO:0045745
- GO:0045944
- GO:0050728
- GO:0051281
- GO:0051897
- GO:0051898
- GO:0070373
- GO:0070374
- GO:0070474
- GO:0071356
- GO:0071375
- GO:0071392
And 3 more, listed on the interactive page.
- GO:0005634
- GO:0005635
- GO:0005654
- GO:0005730
- GO:0005769
- GO:0005783
- GO:0005789
- GO:0005794
- GO:0005802
- GO:0005829
- GO:0005886
- GO:0030659
- GO:0045095
- GO:0048471
- GO:0055037
- GO:0003682
- GO:0004930
- GO:0005496
- GO:0005515
- GO:0030284
- GO:1990239
Related records
Trials (1,114)
- "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
- (VELA) Study of BLU-222 in Advanced Solid Tumors
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
- 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
- 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
- 3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
- A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
- A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
- A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
- A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer
- A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
- A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
- A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg
- A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
- A Definitive Estrogen Patch Study (ADEPT)
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)
- A Drug-drug Interaction Study of DP-R213
Drugs (5)
- 2-methoxyestradiol
- Estradiol
- Fulvestrant
- Raloxifene
- Tamoxifen